The Ritedose Corporation has opened a current Good Manufacturing Practice laboratory at its Performance Park site in South Carolina, an investment of more than USD 17m. The facility triples the contract manufacturer's analytical chemistry and microbiology footprint and adds a stability programme with 10 qualified ICH chambers.
Why this mattersTripling analytical chemistry and microbiology capacity lets Ritedose run stability programmes in-house, supporting pharmaceutical customers from development to launch without outsourcing testing.
- Investment in the new cGMP laboratory exceeds USD 17m
- The laboratory triples Ritedose's analytical chemistry and microbiology footprint
- It occupies the newest building at Ritedose Performance Park in South Carolina
- The stability programme has 10 qualified ICH chambers covering long-term, accelerated, intermediate, refrigerated and controlled room temperature studies
- The laboratory also supports freeze-thaw and photostability testing
The FDA has formally declared the four-year albuterol inhalation solution shortage resolved, and US contract manufacturer Ritedose says the sterile blow-fill-seal (BFS) capacity it built during the shortage is now permanent infrastructure. The Columbia, South Carolina-based CDMO added a seventh Syntegon packaging line and a new logistics centre at its Performance Park site, and gained FDA approval in 2025 for a fourth albuterol strength, completing a four-strength product line.
Why this mattersSustained domestic BFS capacity for a critical respiratory drug reduces reliance on diversified or offshore sourcing for US hospital systems.
- FDA declared the albuterol inhalation solution 0.5% shortage, which began in 2022, formally resolved.
- Ritedose installed a seventh Syntegon packaging line as part of its capacity expansion.
- Ritedose commissioned a logistics and distribution centre at its Performance Park site.
- FDA approved Ritedose's 2.5 mg/0.5 mL concentrated albuterol dosage in 2025, completing a four-strength portfolio.
- Ritedose describes itself as the largest US manufacturer of BFS products.
- The US albuterol patient base exceeds 26 million, including about 7 million paediatric asthma patients.